Elicio Therapeutics
ELTX
18 hedge funds and large institutions have $2.78M invested in Elicio Therapeutics in 2023 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 2 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
0.02% more ownership
Funds ownership: 3.94% → 3.96% (+0.02%)
0% more funds holding
Funds holding: 18 → 18 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
1% less capital invested
Capital invested by funds: $2.8M → $2.78M (-$18.6K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$224K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$107K |
| 3 |
Renaissance Technologies
New York
|
+$107K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$13.1K |
| 5 |
BlackRock
New York
|
+$5.98K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$254K |
| 2 |
Millennium Management
New York
|
-$172K |
| 3 |
CM
CM Management
Gulf Breeze,
Florida
|
-$97.8K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$14.3K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$3.47K |
ELTX Hedge Fund Activity: Q4 2023 in Review
18 of the 6,864 institutional investors tracked by Wall St. Rank reported a position in Elicio Therapeutics (ELTX) for Q4 2023, worth a combined $2.78M — down 0.66% from $2.8M a quarter earlier.
Fund positioning in ELTX was balanced in Q4 2023: 2 funds opened new positions, 2 closed out, 6 added to existing stakes and 4 trimmed.
The largest buyer was Vanguard Group, adding an estimated $224K. The largest seller was Nantahala Capital Management, exiting entirely with an estimated $254K sold.
- 18 institutional investors held Elicio Therapeutics (ELTX) as of Q4 2023, unchanged from Q3 2023.
- Funds reported $2.78M of Elicio Therapeutics stock for Q4 2023, down 0.66% quarter-over-quarter.
- 2 funds opened new Elicio Therapeutics positions in Q4 2023 and 2 closed out, a net change of 0 holders.
- The largest Elicio Therapeutics buyer in Q4 2023 was Vanguard Group, an estimated $224K added.
- The largest Elicio Therapeutics seller in Q4 2023 was Nantahala Capital Management, an estimated $254K sold.
Based on aggregated 13F filings for Q4 2023.